Facebook
Twitter
LinkedIn
ForwardPAINWeek 2024 Digital All Access
PAINWeek remains the US pain conference with the most expansive curriculum providing practical knowledge and tools for healthcare professionals managing acute and chronic pain. Attendees will be able to engage in education that fosters safe, effective, and equitable pain management and treatment practices in clinical practice by providing evidence-based and rigorously tested clinical medical education from expert, experienced, and adequately credentialed medical professionals.
PAINWeek Digital All Access is an online library featuring 80 hours of credit from the live PAINWeek 2024 conference. This allows a learner to:
- Earn CME/CE credit hours at your convenience
- Learn anytime, anywhere, from any device
- Access courses you were not able to attend at the live event
- Access courses if you were not able to attend the live event
Target Audience
This activity is designed for an audience of physicians, physician assistants (PAs), nurse practitioners (NPs), nurses, pharmacists, hospitalists, psychologists, and other healthcare professionals involved in pain management.
Learning Objectives
After participating in the PAINWeek 2024 Digital All Access, learners should be better able to:
- Identify sources of pain via physical and neurological examinations, laboratory tests, imaging, electrodiagnostic procedures, and appropriate psychological assessments.
- Select the appropriate methodology to evaluate chronic pain, including physical exam, clinical history, and work-up.
- Describe and apply comprehensive pharmacological and non-pharmacological pain management and treatment options for various conditions that are characterized by acute, episodic, and chronic pain symptoms.
- Employ safe, effective, and equitable pain management and treatment strategies in clinical practice.
- Employ safe and appropriate evidence-based pain management strategies in patients with multiple chronic pain conditions to minimize the risk of drug-to-drug interactions (DDIs), polypharmacy effects, and substance use disorders (SUDs).
- Employ safe and appropriate evidence-based pain management strategies in patients with multiple comorbidities.
- Recognize implicit biases in clinical practice that may impede the optimal management of pain and patient outcomes.
- Implement interprofessional team strategies for improving care coordination and communication to advance chronic pain care and improve outcomes.
- Cite current medical/legal issues impacting pain management, including updated CDC guidelines, and the ethics of consensual/nonconsensual opioid tapering.
- Analyze the potential impact of artificial intelligence (AI) integration in healthcare, with a focus on its role in pain assessment. Evaluate how AI can address biases in subjective assessments by exploring its applications in various physiological indicators such as voice, facial expressions, and brain waves.
- Evaluate the challenges and opportunities of utilizing AI technology in subjective disease states like pain management. Examine how AI can enhance objectivity in pain assessment, potentially improving patient outcomes by reducing provider-related biases and disparities in care.
- Investigate the ethical considerations around using AI to mitigate biases based on race, gender, and social class in healthcare, and discuss the implications of shifting towards more objective assessment methods in improving care equity.
- Evaluate the potential implications of integrating artificial intelligence (AI) into medical practices, specifically focusing on acute and chronic pain care.
- Explore the theories behind AI creation and technologies such as language analysis and facial recognition in predicting illness. Critically analyze whether AI reinforces or mitigates biases related to race, gender, social class, and sexual orientation in healthcare settings.
- Examine the ethical considerations surrounding the implementation of artificial intelligence in pain assessment and medical decision-making. Discuss the concept of bias propagation versus elimination when computers replace human judgment and compassion. Consider the challenges and opportunities in leveraging machine learning technologies ethically to ensure fair and consistent care across diverse patient populations.
- Critically analyze whether artificial intelligence has the potential to exacerbate existing healthcare disparities or contribute to more equitable care delivery.
- Explore the complexities of algorithmic decision-making in pain assessment and discuss strategies for ensuring that AI integration in healthcare practices aligns with ethical principles and values of fairness and inclusivity.
- Engage in a thoughtful discussion with fellow participants to identify potential benefits and drawbacks of artificial intelligence (AI) in pain assessment. Share personal perspectives and experiences to explore how AI may impact equity and outcomes for disadvantaged groups in healthcare.
- Participate in interactive activities such as audience polling, group discussions, and sessions to delve into the ethical implications of AI integration in subjective disease states like chronic pain. Collaborate with peers to generate ideas on harnessing the power of AI for improving patient care while addressing biases and disparities.
- Contribute to a group consensus on the role of artificial intelligence in eliminating bias and enhancing outcomes for disadvantaged groups in pain assessment. Reflect on best practices for implementing AI in acute and chronic pain care and discuss strategies for leveraging AI technology ethically to promote fairness and inclusivity in healthcare practices.
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Course Concentrations
- AI and Technology
- Behavioral Pain Management
- Chronic Pain Management
- Government/Medical/Legal
- Headache/Migraine
- Integrative Pain Management
- Interventional Pain Management
- Pain and Chemical Dependency
- Pelvic Pain/Women's Health
- Pharmacotherapy
- Psychedelics
- Special Interests
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 80 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 80 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nurses
Credit being awarded: 80 ANCC contact hours.
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 80 contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 80 AAPA Category 1 CME credits. Approval is valid until Expiration Date 11/11/2025. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 80 contact hour(s) (which includes 30 hour(s) of pharmacology).
Psychologists
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
Commercial Support
This activity is supported by educational grants from Averitas Pharma, Inc., Boston Scientific, and Vertex Pharmaceuticals Incorporated.
Disclosures
All planners and faculty for this educational activity, except for those listed below, have no financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
System Requirements:
PC
| MAC
|
Fee & Refund/Cancellation Policy
- A refund is not permitted if you have completed course(s) and claimed your CME/CE credit hours.
- Refunds will be permitted within 30 days of receiving access to your product.
Disclosure of Relevant Financial Relationships:
All planners and faculty for this educational activity, except for those listed below, have no financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Name of Faculty or Presenter | Reported Financial Relationship |
Annika Ehrlich, DNP, FNP-C, CNRN, AQH | Consultant - Abbvie, eNeura; Speaker - Abbvie |
Antje M. Barreveld, MD | Advisor - Lin Health |
Charles Argoff, MD | Advisor - X Gene Pharma; Consultant - Vertex Pharma, Glaxo Smith Kline, Nevro, Tris Pharma, Scilex; Researcher - Lilly, Lundbeck, Vertex; Speaker - Abbvie, Lundbeck, Scilex |
Elise De, MD | Advisor - Flume Catheter, Glyclologix; Individual stocks and stock options – ERYP; Researcher - Ironwood - clinical trial, NIDDK - DSMB Chair |
Georgine Lamvu, MD, MPH | Consultant - SoLa Pelvic Therapy |
Jeff Gudin, MD | Consultant - Collegium, Hisamitsu, Protega, Sanofi, Virpax |
Jeffrey Bettinger, PharmD | Advisor - PainScript LLC; Consultant - Hisamitsu America, Inc., Scilex Holding Company |
Jeffrey Gudin, MD | Consultant - Collegium, Hisamitsu, Protega, Quest Diagnostics, Sanofi, Virpax |
Jeremy Adler, DMSc, PA-C | Speaker - Saluda, Neurometrix, Collegium |
Jody Green, PhD, FACCT | Researcher - Collegium Pharmaceutical, Inc |
Johnathan Goree, MD | Consultant - Abbott, Stratus Medical, Saluda Medical |
Jorge Carrillo, MD | Consultant - Abbvie |
Laura Meyer-Junco, PharmD, BCPS, CPE, FASCP | Advisor - Haleon Consumer Health |
Mattias Ohlsson, PhD | Advisor and Individual stocks and stock options - PainDrainer AB |
Nebojsa (Nick) Knezevic, Md, PhD | Advisor - Tris Pharma, Inc. |
Neel Mehta, MD | Consultant - Boston Scientific, Salix Pharma |
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS | Consultant - Abbvie, Pfizer, Lilly, Theranica, Upsher-Smith, Tonix |
Ramon L. Cuevas-Trisan, MD | Speaker - AbbVie |
Ravi Prasad, PhD | Advisor - Menda Health; Consultant - Nitto, Inc |
Robert Bonakdar, MD, FAAFP, FACN | Consultant - AppliedVR, Kaneka, Metagenics, Standard Process, WellKasa |
Sean Li, MD, FIPP | Consultant - Abbott, Avanos, Averitas Pharma, Biotronik, Nalu, NeuroOne, Nevro, PainTeq, Saluda, SPR Therapeutics, Vertos; Individual stocks and stock options - Nalu Medical, NeuroOne; Researcher - Avanos, Averitas Pharma, Biotronik, Nalu, NeuraLace, Nevro, PainTeq, Saluda, SPR Therapeutics |
Theresa Mallick-Searle, MS, PMGT-BC, ANP-BC | Speaker - Averitas, AbbVie |
Zohra Hussaini, APRN | Consultant - Alcon, Alexion, Allergan, Allgenesis, Alnylam Pharmaceuticals, Alzheon, Annexon Biosciences, AsclepiX, Augen Therapeutics, Bayer, Bausch and Lomb, Beacon Therapeutics (AGTC), Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Carl Zeiss Meditec, Celltrion Healthcare Co., Coherus, Complement Therapeutics, DelSiTech, Galimedix, Genentech/Roche, Innovent, Invirsa, iRenix, Isarna, IvericBio, Janssen, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kodiak, Kriya Therapeutics, Nanoscope Therapeutics, Nico’s, Novartis , Ocugenix, OcuTerra Therapeutics, Omeros, Osanni Bio, Outllok, Oxurion, Panther Pharmaceuticals, Ray Therapeutics, Regeneron, RegenxBio, Resonance Medicine Inc., RetinaAI Medical AG, Retinal Sciences, ReVana, Roivant, Samsung Bioepis, Sandoz, SGN Nanopharma Inc., SmileBiotek Zhuhai Ltd, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa, Tilak, Unity Biotechnology, Vanotech, VisgenX, 2020 Onsite, 4D Molecular Therapeutics; Executive role - Ocular Therapeutix; Individual stocks and stock options - Ocular Therapeutix (S), Oculis (S), Ocuphire (S), Revopsis (S) |
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
Available Credit
- 80.00 AANP
- 31.00 AANP Pharmacology Hours
- 80.00 ACCME (All Other)
- 38.00 MATE ACT credit
- 80.00 ACCME (MD/DO Only)
- 80.00 ACPE Pharmacy
- 80.00 ANCC
- 80.00 APA